Page 1 of 2

1W.
No. 1-6-63

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d)			Attny, Docket No. 2001B110	
In Re Application of: Shutt et al.				
U.S. Serial No. 09/997,436	Filing Date 11/29/01	Examiner Not Yet Assigned	Group Art Unit 1724	

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR § 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three 冈 months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. 37 CFR § 1.97(c) The Information Disclosure Statement submitted herewith is being filed after three months П of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of: a Final Action under § 1.113, 1. a Notice of Allowance under § 1.311, or 2. an action that otherwise closes prosecution in the application, and is accompanied by either: the fee as set forth in § 1.17(p), or the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR § 1.97(d) The Information Disclosure Statement submitted herewith is being filed after a Final  $\Box$ Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign

filing of the information disclosure statement.

patent office in a counterpart foreign application not more than three months prior to the

	v. c Disalogura Statement USPTO form
Applicant hereby requests consideration of the 1449, submitted herewith.	Information Disclosure Statement, USPTO form
∠ Legible copies of the references are enclosed.	ed.
☐ This application is a: ☐ Continuation/ Divisional, ☐ Continuation-in-Part,	
of U.S.S.N not enclosed. Reference not enclosed.	s are available in the parent application(s) if
The Commissioner is hereby authorized to chathis paper, or credit any overpayment, to Depo of this form is enclosed.	arge any additional fees which may be required by osit Account Number 05-1712. A duplicate copy
	Respectfully submitted,
January 22, 2003  Date	Paul T. LaVoie
	Registration No. 38,681
ExxonMobil Chemical Company	
Law Technology	
P.O. Box 2149	
Baytown, Texas 77522-2149	
(281) 834-5080 Voice	
(281) 834-2495 Facsimile	

paul.t.lavoie@exxonmobil.com

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)

DATE CONSIDERED

Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line though citation if not in conformance and

I:\BPC\Law\Document\Patents\Prosecution\1999B021-US-2002SEPT18-1449 Form

not considered. Include copy of this form with next comment to applicant

AL

AM

AN

**EXAMINER** 

\*EXAMINER: